

Helsinn, Mundipharma China Pharmaceutical announce the approval of ALOXI

04 December 2018 | News

This is the first Helsinn cancer supportive care product to be approved for marketing in China



Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care products, and Mundipharma China Pharmaceutical, the market leader of pain management, have jointly announced that ALOXI IV has received approval from the National Medical Products Administration (NMPA).

This is the first Helsinn cancer supportive care product to be approved for marketing in China. Mundipharma China Pharmaceutical has exclusive marketing, promotion and sale rights for ALOXI in China.

Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: "ALOXI IV is our first cancer supportive care product to be approved by the NMPA and we are delighted that it will soon be available to patients also in China. In the countries where ALOXI® IV has been launched so far, ALOXI has been central to the prevention of CINV for many years and has helped define the standard of care for this condition. In China, we are collaborating with our longstanding and trusted partner, Mundipharma China Pharmaceutical, and we look forward to working with them to bring this product to the many patients in China that suffer from CINV."

Peter Wang, Mundipharma Pharmaceutical Greater China CEO, commented: "I'm more than happy to witness such a milestone of Mundipharma China Pharmaceutical to align a strategic partnership with Helsinn, and therefore to introduce ALOXI IV focusing on CINV treatment with cutting-edge technology and high quality to China market. This milestone not only enriches Mundipharma China's portfolio, but definitely is to benefit millions of China's patients, which is in line with the company's insight and vision, 'Bring more to life.'"

ALOXI injection 0.25 mg/5 ml was approved on November 8th, 2018 in China and is indicated in adults for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, and prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy